The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins.
Read more on the latest collaboration between Servier and Aitia in Mind Health. For the english version, please refer to the Google Translate tab at the top right of the browser.
Full article available here.